Tyler Whitfield

About

Self-motivated clinical research (CCRC) and technology enthusiast (BS in software engineering) with 5+ years in site level research covering a wide range of responsibilities. High aptitude for problem-solving, identifying bottlenecks in complex systems, and acquisition and integration of new skills. Proven versatility to dynamic team structures and role variability.

Work Experience

Projects

• Lead Coordinator: Real-world Evidence of Duration of XXX for treatment of ADHD: An open-label pragmatic study to assess the real-world effectiveness of XXX in treatment of adult and adolescent patients with ADHD in the United States
• Lead Coordinator: Evaluation of XXX ER 200 and 400 mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
• Lead Coordinator: Evaluation of XXX ER 400 and 600 mg Efficacy and Safety in Adolescents with ADHD - A double-blind, placebo-controlled, pivotal trial
• Lead Coordinator: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD)
• Lead Coordinator: A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy and Safety of XXX Nasal Spray for the Treatment of Acute Migraine in Subjects Ages 6 to 11 Years, with an Open-Label Extension
• Lead Coordinator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of XXX Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
• Lead Coordinator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of XXX Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age
• Lead Coordinator: A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of XXX for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
• Lead Coordinator: An Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome
• Lead Coordinator: A single-arm, open label, multicenter study of the safety and efficacy of XXX for the acute treatment of migraine in adolescents
• Lead Coordinator: preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems
• Lead Coordinator: Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the XXX (XXX Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches
• Lead Coordinator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
• Lead Coordinator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
• Lead Coordinator: A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of XXX as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome
• Coordinator: A Randomized, Double-Blind, Placebo-Controlled Study of XXX in Patients 6 to 17 Years of Age with Episodic Migraine
• Coordinator: An Open-Label Trial to Assess the Safety of XXX (XXX) Oral Solution in Combination with Cannabidiol, as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome or Lennox-Gastaut Syndrome
• Coordinator: An Open-Label Extension Trial to Assess the Long-Term Safety of XXX (XXX) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome
• Coordinator: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral XXX for the Prevention of Migraine in Participants with Episodic Migraine
• Coordinator: A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral XXX for the Prevention of Migraine in Participants with Episodic Migraine
• Coordinator: A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral XXX in the Treatment of Pediatric Subjects with Tourette’s Disorder
• Coordinator: An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of XXX in Pediatric, Adolescent and Adult Subjects with Epilepsy
• Coordinator: Expanded Access Program for patients with Dravet syndrome who do not qualify for participation in one of the ongoing XXX (XXX) clinical trials
• Coordinator: Prevalence of XXX Deficiency in Cerebral Palsy Patients with Unknown Etiology
• Coordinator: Blood Collection Protocol for Clinical Laboratory Research Evaluating Biomarkers in Individuals with Dravet Syndrome
• Coordinator, Videographer: A Randomized, Double-Blind, Placebo-Controlled Study of XXX for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
• Consultant, Data Manager: A Prospective, Open-Label Study of XXX for the Treatment of Chronic Migraine Headaches
• Technical Liaison: A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic XXX Oral Solution in Pediatric Patients with Treatment-Resistant Childhood Absence Seizures
• Unblinded Pharmacist: A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine.
• Recruiter: A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of XXX Administered Intravenously in Patients with Chronic Migraine
• Recruiter: An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of XXX Oral Suspension when Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to less than 12 years) with Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic-Clonic Seizures

Education

• 2020

  Kennesaw State University

  Bachelor of Science

  Software Engineering

• 2014

  University of North Georgia

  Associate of Science

  Mathematics, Computer Science

Skills